Skip to Content
Søg Menu
December 2022

Følg med når vi dækker ASH 2022 | American Society of Hematology Meeting & Exposition

Seneste fra ASH 22

Axicabtagene ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients

  • / Roch Houot

Abstracts fra ASH 2022

The ASH Annual Meeting provides several resources on COVID-19 in hematology

/ BestPractice Nordic
ASH21COVID-19
ASH2021 Poster Hall

Long-term remission found with combination therapy for young patients with CLL

/ BestPractice Nordic
ASH21CLL

Isatuximab + RVd bedrer MRD negativitet og prognose ved myelomatose

/ BestPractice Nordic
ASH21Myelomatose

New prophylactic therapy for patients with hemophilia A and B

/ BestPractice Nordic
ASH21Hæmofili

MEDtalks: Seneste fra ASH 2022

AML

Superior efficacy of Iptacopan in PNH patients

/ Hæmatologi / Régis Peffault De Latour

CLL – Update fra ASH 2022

/ Hæmatologi / Carsten Utoft Niemann

New potential key pathway in patients with ALL

/ Hæmatologi / Signe Modvig

Significant longer PFS among patients who received zanubrutinib vs ibrutinib

/ Hæmatologi / Jennifer R. Brown

Several interesting combinations of therapies with Calquence for patients with CLL

/ Hæmatologi / Matthew S. Davids
Se oversigt

CLL

UK NCRI AML19 Trial – Liposomal daunorubicin and cytarabine had a significant survival benefit

/ Hæmatologi / Jad Othman

Venetoclax plus obinutuzumab er den mest omkostningseffektive behandling af CLL uden del17p/TP53-mutationer

/ Hæmatologi / Matilde Slot

AML patients with FLT3-ITD and wild-type NPM1 has a significant improvement of LFS, OS and GRFS

/ Hæmatologi / Ali Bazarbachi

AML-highlights fra ASH22 – i dansk perspektiv

/ Hæmatologi / Hans Beier Ommen

Dramatic improvement in 1-year survival for patients with acute promyelocytic leukemia

/ Hæmatologi / Anand P. Jillella

Myelomatose

New combination shows promising efficacy in patients with triple-class refractory R/R multiple myeloma

/ Hæmatologi / Paul G. Richardson

Lower-risk myelodysplastic syndromes treated with Reblozyl, luspatercept – Real-world outcomes

/ Hæmatologi / Sudipto Mukherjee

LBA ASH22: Significantly better overall survival in patients with B-lineage ALL treated with Blincyto, blinatumomab, as Consolidation Therapy

/ Hæmatologi / Mark Robert Litzow

BCMA-targeted and CAR-T cells therapies for multiple myeloma give a very exciting future and new hope for the patients

/ Hæmatologi / Sagar Lonial

Evidence to use MRD after induction therapy of AML

/ Hæmatologi / Jacqueline Cloos

Lymfom

Frederick Locke

R/R Large B-cell Lymphoma: Interesting results from ASH 2022 for treatment with Yescarta (axicabtagene ciloleucel)

/ Frederick L. Locke
ASH22Lymfom Play the Video
Catherine Broome

Clinically and statistically significant improvement for efgartigimod in adults with ITP

/ Catherine M. Broome
ASH22 Play the Video
Hent flere

Mere fra ASH 2022

Johannes Schetelig

R/R AML: The benefit of intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation

/ Johannes Schetelig
ASH22AML Play the Video
Eugen Tausch

Genomic aberrations as prognostic factors for time-limited Venclyxto, Venetoclax-based combinations

/ Eugen Taucsh
ASH22CLL Play the Video

A non-restrictive diet does not increase infections in patients with neutropenia after stem cell Transplantation

/ Federico Stella
ASH22 Play the Video
Hent flere

MEDtalks fra ASH 2021

Promising Preliminary Efficacy in Patients with Relapsed/Refractory Multiple Myeloma

/ Hæmatologi / Paul G. Richardson

Maintenance therapy: Oral azacitidine in patients with AML improves long-term overall survival

/ Hæmatologi / Andrew Wei

CAR-T-terapi til behandling av storcellet B-cellelymfom

/ Hæmatologi / Alexander Fosså

Relapse vaccine is a promising treatment for patients with AML

/ Hæmatologi / Bjørn Tore Gjertsen

CAR T Cell Therapy – a new standard of care for 2L treatment of R/R in Large B-cell Lymphoma

/ Hæmatologi / Manali Kamdar

ReVenG: Retreatment with venetoclax plus obinutuzumab in patients with relapsed CLL

/ Hæmatologi / Matthew S. Davids

How can we use Minimal Residual Disease in the treatment of CLL?

/ Hæmatologi / Paolo Ghia

Safe to use Belantamab Mafodotin for transplant-ineligible patients with newly diagnosed multiple myeloma

/ Hæmatologi / Evangelos Terpos

The use of FDG PET/CT positivity as an indication for consolidation in myeloma patients after ASCT

/ Hæmatologi / Fredrik Schjesvold

PFS of 63% after 5 years for patients with multiple myeloma in maintenance therapy with lenalidomide and dexamethasone

/ Hæmatologi / Laura Rosiñol

Nye behandlinger med antistoffer til patienter med myelomatose patienter

/ Hæmatologi / Torben Plesner

Real-world outcomes of axi-cel treatment of large B-cell lymphoma

/ Hæmatologi / Frederick L. Locke

ASH 2021: Flere opsigtsvækknede resultater for behandling af lymfomer

/ Hæmatologi / Judit Mészáros Jørgensen

The best treatment sequence for first-, second-, and third-line therapy for patients with relapsed multiple myeloma

/ Hæmatologi / Claudio Cerchione

MRD analysis in 1L Treatment of CLL in Elderly or Unfit patients

/ Hæmatologi / Talha Munir

Abstracts fra ASH 2021

Polatuzumab vedotin with R-CHP for patients with diffuse large B-Cell lymphoma

/ Hæmatologi / BestPractice Nordic

ZUMA-7: CAR T-cell therapy in earlier lines of therapy benefits patients with relapsed/refractory large B-cell lymphoma

/ Hæmatologi / BestPractice Nordic
Se oversigt

Gå ikke glip af det nyeste fra Hæmatologi

Skriv dig på og få nye artikler, MEDtalks og magasiner i din indbakke

Send mig seneste nyt fra hæmatologi

Indhold fra ASH 2020

Philipp Sergeev

Combination treatment of AML with spleen tyrosine kinase

/ Philipp Sergeev
ASH21AML Play the Video
Agoston Gyula Szabo

Muligt gennembrud i behandlingen af myelomatose

/ Agoston Gyula Szabo
ASH21Myelomatose Play the Video
Martin Hutchings

Lovende effekt og sikkerhed ved kombinationsbehandling med bispecifikke antistoffer til patienter med DLBCL

/ Martin Hutchings
ASH21Lymfom Play the Video
Hent flere

Back to top